Q-omics provides the consensus-scored MIR6793 profile across patient tissues and cancer cell-line models. MIR6793 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR6793 is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, MIR6793 RNA expression shows 9,353 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, CHOL, and UVM as cancer lineages where MIR6793 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6793 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6793 survival associations across molecular data types. MIR6793 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6793 RNA expression–survival associations across cancer types. High MIR6793 expression shows unfavorable associations in KICH, LUSC, LUAD and THCA, but favorable associations in GBM and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR6793 RNA expression.
This table summarizes MIR6793 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6793. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6793 shows lower tumor expression in KIRC and higher tumor expression in CHOL, LIHC, STAD, KIRP and KIRC. The CHOL box plot shows higher MIR6793 RNA expression in tumor versus normal tissue (log2 FC = +1.730, t-test p < 0.001).
This table shows molecular features associated with MIR6793 in patient tissues and cancer cell lines. In patient samples, MIR6793 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
